Sermorelin sits in an unusual spot in United States drug law: it was once an FDA-approved pharmaceutical and is now legal to use in patient care, yet it exists as no approved commercial product at all. The honest bottom line is that it is neither banned nor freely available. It is a prescription-only peptide that reaches patients solely through pharmacy compounding, and material bought outside that channel falls outside the law regardless of how the seller labels it.
Sermorelin is a legal, non-controlled, prescription-only peptide with no FDA-approved commercial product, available lawfully only through 503A or 503B compounding pharmacies dispensing against a valid individual prescription.
The record shows sermorelin acetate carried FDA approval for roughly two decades, so its current status reflects a discontinuation rather than a ban, a distinction that carries real legal weight. First approved in the 1990s and sold under the brand name Geref, it served initially as a diagnostic agent measuring the growth hormone response to a sermorelin injection, and later in a formulation indicated for idiopathic growth hormone deficiency in children. When the FDA addressed the withdrawals in its regulatory listings, it determined that the products were not withdrawn for reasons of safety or effectiveness.
Sermorelin was first approved in the 1990s as the brand Geref and was discontinued in the mid-2000s, with the FDA determining the withdrawal was not for reasons of safety or effectiveness.
No manufactured, FDA-approved sermorelin product is commercially available in the United States today, and no company has brought an approved finished form back to market since the original brands left. The practical consequence is that a patient cannot pull sermorelin off a retail pharmacy shelf the way they would a mass-produced medication, and because there is no approved product it generally sits outside insurance formularies and is paid out of pocket. What the absence of a commercial product does not do is make the molecule illegal: it remains lawful to use through the compounding framework.
There is no FDA-approved commercial sermorelin drug product in the United States; the molecule remains lawful only as a compounded preparation, which places it outside typical insurance formularies and into out-of-pocket cost.
A common assumption is that any injectable tied to growth hormone must be tightly scheduled, but sermorelin appears on none of the DEA's schedules. As a growth hormone-releasing hormone analog, it prompts the pituitary to release the body's own growth hormone rather than acting as an exogenous anabolic agent, which separates it from the Schedule III anabolic-androgenic steroids. It also sits apart from recombinant human growth hormone, whose distribution is restricted under a specific federal statute that sermorelin, as a releasing hormone rather than growth hormone itself, does not fall under.
| Substance | DEA status | Distribution constraint |
|---|---|---|
| Sermorelin | Not scheduled | Prescription and general compounding law only |
| Anabolic steroids | Schedule III | Controlled-substance recordkeeping and reporting |
| Human growth hormone | Not traditionally scheduled | Restricted by a specific federal HGH distribution statute |
Sermorelin is not a DEA-scheduled controlled substance and, as a releasing-hormone analog rather than growth hormone itself, is not subject to the federal statute restricting human growth hormone distribution, though it still requires a valid prescription.
The lawful route to sermorelin runs through pharmacy compounding, the practice of preparing a customized medication when an appropriate FDA-approved product is not commercially available, authorized under specific sections of the federal Food, Drug, and Cosmetic Act. Two facility types operate in this space, and the difference between them determines both the oversight and the batch scale that apply. The requirement that 503A compounding be tied to an individual patient prescription is deliberate: it separates lawful compounding from the unlicensed manufacture of an unapproved new drug, which is prohibited.
Sermorelin is dispensed lawfully only through 503A compounding pharmacies preparing individualized preparations against a valid prescription for a named patient, or 503B outsourcing facilities registered with the FDA under stricter manufacturing standards.
Compounding regulation for sermorelin turns heavily on how the FDA treats the bulk drug substance used to prepare it. When a pharmacy compounds from raw active ingredient rather than an approved finished drug, that bulk substance must generally appear on an approved monograph, be a component of an approved drug, or be placed on the FDA's list of bulk drug substances eligible for 503A compounding, and its placement, exclusion, or pending status directly shapes whether pharmacies can lawfully compound with it. In recent years the FDA has intensified scrutiny of compounded peptide products as a class, raising questions about immunogenicity, characterization, and appropriate use, which has narrowed availability across the category.
Lawful sermorelin compounding depends on the bulk drug substance being eligible under FDA rules, with the activity crossing into unlawful manufacturing once a pharmacy produces standardized volume products that function as unapproved new drugs.
Sermorelin is a prescription-only medication that cannot be lawfully sold over the counter or directly to consumers. Because it is dispensed through compounding, it must be ordered by a licensed prescriber and prepared against a valid prescription written for a specific, identified patient, and that prescription must arise from a legitimate physician-patient relationship rather than a signed-off online order. The published model treats ongoing physician supervision as part of lawful use, since sermorelin acts on the body's growth hormone axis and appropriate prescribing typically involves baseline assessment and periodic monitoring.
Sermorelin is prescription-only and cannot be sold over the counter, requiring a valid prescription written for a named patient within a legitimate physician-patient relationship that includes baseline assessment and ongoing monitoring.
Sourcing sermorelin outside the regulated prescription channel introduces the exact legal and safety exposure the compounding pathway is built to avoid. A large gray market sells peptides through research-chemical vendors and websites labeling their products "not for human consumption," a disclaimer used to sidestep drug regulation while still selling to people who intend to inject the material, yet it offers no genuine legal shield and no protection from harm. On the seller side, distributing an unapproved new drug or an adulterated or misbranded product can draw federal enforcement action; on the buyer side, obtaining an injectable drug without a prescription is unlawful practice regardless of the label. The safety gap runs alongside the legal one, since unregulated material can be contaminated, mislabeled, under- or over-concentrated, or entirely different from what is advertised.
Sourcing sermorelin from research-chemical vendors or "not for human use" sellers is unlawful for buyer and seller alike, with the disclaimer offering no legal shield and the unregulated material carrying unverified purity, dosing, sterility, and identity.
Educational use only. This article describes what the published scientific and clinical literature reports about Sermorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
